ENGLEWOOD, Colo., March 3, 2021 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology-based therapies
for prevalent inflammatory conditions, today announced that
management will present at the virtual H.C. Wainwright Global Life
Sciences Conference scheduled Tuesday,
March 9, 2021 through Wednesday,
March 10, 2021.
The video webcast presentation will be available for viewing
on-demand beginning Tuesday, March 9,
2021 at 7:00 am (EST) for
those registered for the event and will be accessible on the
Presentations & Media page in the Investors section of the
Company's website
(https://ampiopharma.com/investors/presentations-media/). The
webcast replay will be archived for 90 days following the
event.
For more information and to register for the conference, please
visit Ampio's website here.
Webcast link:
https://journey.ct.events/view/9d6b477a-99ab-451d-a4da-6fbe4bbd9cb8
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage
biopharmaceutical company primarily focused on the development of
Ampion, our product candidate, to treat prevalent inflammatory
conditions for which there are limited treatment options. Ampio's
lead drug, Ampion, is backed by an extensive patent portfolio with
intellectual property protection extending through 2035 and will be
eligible for 12-year FDA market exclusivity upon approval as a
novel biologic under the biologics price competition and innovation
act ("BPCIA").
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as
well as those associated with regulatory approvals and other FDA
decisions, the Biological License Application ("BLA"), the ability
of Ampio to enter into partnering arrangements,
clinical trials and decisions and changes in business
conditions and similar events, the ability to receive regulatory
approval to conduct clinical trials, that Ampion may be used to
treat ARDS induced by COVID-19, all of which are inherently subject
to various risks and uncertainties. The risks and uncertainties
involved include those detailed from time to time in Ampio's
filings with the Securities and Exchange Commission, including
without limitation, under Ampio's Annual Report on Form 10-K and
other documents filed with the Securities and Exchange Commission.
Ampio undertakes no obligation to revise or update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Company Contacts
Investor Relations
Joe Hassett
joeh@gregoryfca.com
484-686-6600
Media Contact
Katie Kennedy
katiek@gregoryfca.com
610-731-1045
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-present-at-the-hc-wainwright-global-life-sciences-conference-301239670.html
SOURCE Ampio Pharmaceuticals, Inc.